Aerosol vaccination is used effectively to immunize poultry against Newcastle disease, but to the authors' knowledge, this vaccination procedure is not well studied in other species. The efficacy of IM and aerosol vaccination of pigs against Mycoplasma hyopneumoniae infection was evaluated. Twenty-one pigs from a Mycoplasma-free herd were randomly allotted by litter and body weight into 3 groups. One group was given aerosolized phosphate-buffered saline solution (PBSS) by inhalation. The second group (AERO) was given aerosolized M hyopneumoniae vaccine by inhalation. The third group (IM) was given the same vaccine by IM injection. Vaccination by IM administration was repeated once, and aerosol vaccination was repeated twice at 2-week intervals. Two weeks after the last vaccination, all pigs were intratracheally challenge-exposed with 3 ml of broth culture containing 10(7) color-changing units (CCU) of a low-passage strain of virulent M hyopneumoniae. Pigs were observed daily for coughing. Four weeks after challenge exposure, all pigs were necropsied. Percentage of lung affected by gross pneumonia was measured, bronchioalveolar lavage fluid (BALF) cells were counted, and quantitative culture for mycoplasmas was performed on lung sections. Additionally, M hyopneumoniae-specific antibodies were measured in prevaccination, postvaccination, and postchallenge-exposure serum and BALF by use of indirect ELISA. Mean prevalence of persistent coughing in pigs of the AERO group (4.6 d/pig) was not different from that in pigs of the PBSS group (3.7 d/pig). Prevalence of coughing in IM vaccinated pigs (1.0 d/ pig) was lower (P < 0.05) than that in pigs of the PBSS group. Mean gross lung lesion scores and BALF cell counts were not different between the AERO (15% pneumonia, 5,233 cells/microliter) and PBSS (11% pneumonia, 3,022 cells/microliter) groups, but were lower (P < 0.05) in the IM group (1.5% pneumonia, 400 cells/microliter) than in the PBSS group. Mean lung mycoplasmal counts were not significantly (P < 0.05) different among the PBSS (10(5.6) CCU/g), AERO (10(5.3) CCU/g), and IM (10(3.3) CCU/g) groups. Postvaccination M hyopneumoniae-specific IgG or IgA was not detectable in BALF after either vaccination procedure. Postvaccination M hyopneumoniae-specific serum IgG concentration was not different among the 3 groups. Postchallenge exposure M hyopneumoniae-specific IgG and IgA were detectable in BALF of all pigs, but were not different among the 3 treatment groups. Postchallenge exposure-specific serum IgG concentration was not different between the PBSS (mean OD, 0.739) and AERO (mean OD, 0.672) groups, but was higher (P < 0.05) in the IM group (mean OD, 1.185) than in the PBSS group. Aerosol vaccination failed to induce local and systemic antibody responses detectable by ELISA, and failed to protect pigs against mycoplasmal pneumonia. Intramuscular vaccination failed to induce local and systemic antibody responses detectable by ELISA, but substantially reduced the clinical signs and lesions caused by challenge exposure to virulent M hyopneumoniae.

Withdrawal periods required when doses of 24,000 IU and 66,000 IU of procaine penicillin G/kg body weight were administered to yearling beef steers by intramuscular injection daily for five consecutive days were investigated. These dosages are in excess of product label recommendations, but are in the range of procaine penicillin G dosages that have been administered for the treatment of some feedlot bacterial diseases. The approved dose in Canada is 7,500 IU/kg body weight intramuscularly, once daily, with a withdrawal period of five days. Based on the tissue residue data from this study, the appropriate withdrawal period is ten days for the 24,000 IU/kg body weight dose and 21 days for the 66,000 IU/kg body weight dose when administered intramuscularly to yearling beef steers. In a related study, 18 yearling beef steers received 66,000 IU of procaine penicillin G/kg body weight administered by subcutaneous injection, an extra-label treatment in terms of both dose and route of administration, typical of current practice in some circumstances. Deposits of the drug were visible at subcutaneous injection sites up to ten days after injection, with more inflammation and hemorrhage observed than for intramuscular injections of the same dose. These results suggest that procaine penicillin G should not be administered subcutaneously at high doses; and therefore a withdrawal period was not established for subcutaneous injection.

The effect of triamcinolone acetonide (0.09 mg/ kg of body weight, IM) on serum osteocalcin concentration was studied. Two groups of horses were investigated and included clinically normal horses (group 1, n = 5) and horses with chronic obstructive pulmonary disease (group 2, n = 5). Before treatment, results of a t-test did not reveal any significant difference in serum osteocalcin concentration between the 2 groups. After treatment, a significant (P < 0.05) decrease in serum osteocalcin concentration was observed for both groups. Osteocalcin concentration in individual horses reached a minimum by 24 to 48 hours after treatment. In both groups of horses, serum osteocalcin response to glucocorticoid administration was similar. In 7 of 10 horses, return to pretreatment values was observed after 28 days. Pretreatment values for the other 3 horses were reached between 62 and 150 days.

Twelve horses (6 Standardbreds and 6 Thoroughbreds) received IM injections of furosemide (250 mg) or physiologic saline solution and performed standard exercise tests, to assess the effects of furosemide and breed on blood gas values, PCV, plasma lactate concentration, and heart rate during exercise. After furosemide administration, arterial and venous blood pH values were significantly (P < 0.05) increased. Partial pressures of O2 and CO2 in arterial blood and of CO2 in venous blood (Pa(O2), Pa(CO2), and Pv(CO2), respectively) were unaffected by furosemide treatment, whereas venous partial pressures of O2 (Pv(O2)) were significantly (P < 0.05) less during exercise after furosemide treatment, suggesting an increase in oxygen uptake by the exercising muscles or a change in cardiac output. A significant (P < 0.05) difference was found between Thoroughbred and Standardbred values for arterial and venous pH, Pa(O2), Pa(CO2), plasma lactate concentration, and heart rate, suggesting that Standardbreds exercised at a relatively higher work rate than did Thoroughbreds.

Plasma and lung tissue pharmacokinetics of danofloxacin calves with naturally induced acute pneumonia were determined in 2 separate studies. A maximal pneumonic tissue concentration of 1.17 microgram/g was achieved 1.8 hours after IM injection of 1.25 mg of danofloxacin/kg of body weight. Pneumonic tissue danofloxacin concentrations were 5.5 times greater than those in plasma at 1 and 2 hours after injection. Cranioventral pneumonic tissue had significantly decreased danofloxacin concentration, compared with that of grossly normal tissue from the caudodorsal part of the lungs at 2 of 6 sample times. After IV injection, the apparent steady-state volume of distribution was 3.44 +/- 1.13 L/kg, and the elimination half-life was 6.26 2.27 hours. Maximal plasma danofloxacin concentration of 0.25 microgram/ml was detected 0.80 hour after IM injection. Bioavailability was 91%. Our findings indicated that a large percentage of danofloxacin is rapidly absorbed after IM administration to calves with acute pneumonia. Extensive tissue penetration was suggested by a high steady-state volume of distribution and was indicated by high concentrations in pneumonic tissue.